![]() |
Published Results Show Denosumab Superior To Zometa(R) In Delaying Or Preventing Bone
Amgen (Nasdaq: AMGN) announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa(R) (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases...
More... |
| All times are GMT -7. The time now is 03:22 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021